SURMODICS INC (SRDX) Stock Price, Quote, News and Overview
NASDAQ:SRDX - Nasdaq - US8688731004 - Common Stock - Currency: USD
SRDX Quote, Performance and Key Statistics
30.93
-0.17 (-0.55%)
The current stock price of SRDX is 30.93 USD. In the past month the price increased by 1.31%. In the past year, price decreased by -4.8%.
SRDX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.3 | 226.33B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.39 | 184.47B | ||
| BSX | BOSTON SCIENTIFIC CORP | 38.05 | 151.96B | ||
| SYK | STRYKER CORP | 30.43 | 141.58B | ||
| MDT | MEDTRONIC PLC | 15.84 | 108.50B | ||
| BDX | BECTON DICKINSON AND CO | 14.84 | 59.28B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.34 | 44.85B | ||
| IDXX | IDEXX LABORATORIES INC | 38.84 | 35.41B | ||
| RMD | RESMED INC | 26.18 | 34.92B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.16 | 31.17B | ||
| DXCM | DEXCOM INC | 43.21 | 27.96B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 15.94 | 23.53B |
Related stock screener links
About SRDX
Company Profile
Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 389 full-time employees. The company also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
Company Info
SURMODICS INC
9924 W 74th St
Eden Prairie MINNESOTA 55344 US
CEO: Gary R. Maharaj
Employees: 376
Company Website: https://www.surmodics.com/
Investor Relations: https://surmodics.gcs-web.com/
Phone: 19525007000
SURMODICS INC / SRDX FAQ
What is the stock price of SURMODICS INC today?
The current stock price of SRDX is 30.93 USD. The price decreased by -0.55% in the last trading session.
What is the ticker symbol for SURMODICS INC stock?
The exchange symbol of SURMODICS INC is SRDX and it is listed on the Nasdaq exchange.
On which exchange is SRDX stock listed?
SRDX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SURMODICS INC stock?
9 analysts have analysed SRDX and the average price target is 43.86 USD. This implies a price increase of 41.8% is expected in the next year compared to the current price of 30.93. Check the SURMODICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SURMODICS INC worth?
SURMODICS INC (SRDX) has a market capitalization of 441.99M USD. This makes SRDX a Small Cap stock.
How many employees does SURMODICS INC have?
SURMODICS INC (SRDX) currently has 376 employees.
What are the support and resistance levels for SURMODICS INC (SRDX) stock?
SURMODICS INC (SRDX) has a support level at 27.57 and a resistance level at 30.94. Check the full technical report for a detailed analysis of SRDX support and resistance levels.
Is SURMODICS INC (SRDX) expected to grow?
The Revenue of SURMODICS INC (SRDX) is expected to grow by 3.27% in the next year. Check the estimates tab for more information on the SRDX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SURMODICS INC (SRDX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SRDX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SRDX, evaluating the profitability, health, valuation and growth aspects
- SURMODICS INC (SRDX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SURMODICS INC (SRDX) Sales and EPS estimates to see what analysts future expectations are.
- SURMODICS INC (SRDX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SURMODICS INC (SRDX) Insider and Institutional Ownership to learn about the owners and their transactions.
- SURMODICS INC (SRDX) Stock Chart to make your own analysis
- SURMODICS INC (SRDX) Latest news and press-releases to stay up to date.
Does SURMODICS INC (SRDX) stock pay dividends?
SRDX does not pay a dividend.
When does SURMODICS INC (SRDX) report earnings?
SURMODICS INC (SRDX) will report earnings on 2025-04-30, before the market open.
What is the Price/Earnings (PE) ratio of SURMODICS INC (SRDX)?
SURMODICS INC (SRDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.37).
What is the Short Interest ratio of SURMODICS INC (SRDX) stock?
The outstanding short interest for SURMODICS INC (SRDX) is 3.36% of its float. Check the ownership tab for more information on the SRDX short interest.
SRDX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SRDX. When comparing the yearly performance of all stocks, SRDX is a bad performer in the overall market: 62.31% of all stocks are doing better.
SRDX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SRDX. SRDX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SRDX Financial Highlights
Over the last trailing twelve months SRDX reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS decreased by -156.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.8% | ||
| ROE | -12.89% | ||
| Debt/Equity | 0.26 |
SRDX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to SRDX. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -14.36% and a revenue growth 3.27% for SRDX